WHO has prequalified Coartem (artemether-lumefantrine) Baby, a new formulation designed for newborns and young infants weighing 2 to 5 kilograms, marking the first antimalarial specifically developed for this population and unlocking procurement by UN agencies and national malaria programs. Novartis, which developed the product with Medicines for Malaria Venture, plans to supply it largely on a not-for-profit basis in endemic regions, and the treatment has already begun rolling out in Ghana.
Beyond a regulatory milestone, this is a strategic inflection for donor-funded markets and for how big pharma participates in global health. Prequalification converts scientific novelty into access at scale, enabling inclusion on tender lists and paving the way for guideline updates and in-country registrations. In a category dominated by generics and razor-thin margins, originator-led pediatric innovation creates a defensible niche where clinical differentiation and quality assurance matter more than list price. It also positions Novartis at the center of the access conversation just as funders and governments reassess priorities amid rising malaria incidence and budget pressure.
The timing is consequential. Malaria cases climbed to an estimated 282 million in 2024 with 610,000 deaths, and children under five accounted for most fatalities, predominantly in Africa. Until now, infants under roughly 4.5 kilograms faced a treatment gap, often receiving modified doses of formulations intended for older children, with attendant risks to safety and adherence. For patients and frontline clinicians, an infant-specific, quality-assured ACT addresses a real clinical need; for payers and procurement agencies, prequalification de-risks purchase decisions and supports standardized care pathways. The onus shifts to national programs to update protocols and strengthen case detection in the first months of life, where malaria is under-recognized and data are sparse.
For Commercial and Market Access teams, the path from WHO listing to uptake will hinge on synchronized tender participation, in-country registration, and coordinated introduction packages with donors such as the Global Fund, UNICEF, and national malaria programs. Volume forecasting, last-mile availability, and training materials tailored to maternity wards and neonatal units will determine whether access translates into real utilization. As artemisinin supply chains remain volatile, supply resilience and predictable lead times will become differentiators in tenders.
Medical Affairs will need to drive targeted HCP education on diagnosis and dosing in neonates, generate real-world evidence and pharmacovigilance in fragile infants, and address practicalities like palatability and adherence under outpatient conditions. Post-market data in this age band could shape label refinements and inform WHO guideline iterations, while also guiding future pediatric formulations across malaria and other infectious diseases.
The move also maps to broader industry currents: the resurgence of product-development partnerships to share risk in neglected diseases, the rise of pediatric-first design as a competitive lever even in genericized categories, and a pipeline pivot toward non-artemisinin combinations as resistance pressures intensify. Competitors with generic ACTs may pursue follow-on infant formulations, but excipient safety, bioavailability in neonates, and quality assurance create meaningful barriers that favor first movers with established PQ status.
The strategic question now is speed and scale. If countries quickly embed infant-specific treatment into guidelines and surveillance, this launch could reset the standard of care for the youngest patients and fortify trust in donor-funded procurement. The next test will be whether Novartis can convert this momentum into durable share in pediatric malaria while accelerating new mechanisms that future-proof therapy against resistance—before budget headwinds and supply constraints redraw the access map.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
